HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs.

Abstract
Thrombin is a powerful agonist for platelets, the action of which is mediated by the thrombin receptor protease-activated receptor-1 (PAR-1). Recently, we discovered that E5555 (1-(3-tert-butyl-4-methoxy-5-morpholinophenyl)-2-(5,6-diethoxy-7-fluoro-1-imino-1,3-dihydro-2H-isoindol-2-yl) ethanone hydrobromide) is a potent thrombin receptor antagonist. We evaluated the anti-platelet and anti-thrombotic effects of E5555. E5555 inhibited the binding of a high-affinity thrombin receptor-activating peptide ([(3)H]haTRAP) to PAR-1 with a half maximal inhibitory concentration (IC(50)) value of 0.019μM. E5555 showed potent inhibitory effects on human platelet aggregation induced by thrombin and TRAP with IC(50) values of 0.064 and 0.031μM, respectively, but had no effect on platelet aggregation induced by either ADP or collagen. Similarly, E5555 showed potent and selective inhibitory effects on guinea pig platelet aggregation induced by thrombin and TRAP with IC(50) values of 0.13 and 0.097μM, respectively. The antithrombotic activity of E5555 in vivo was evaluated in a photochemically-induced thrombosis (PIT) model using guinea pigs. Oral administration of E5555 at 30 and 100mg/kg prolonged the time to occlusion by 1.8-fold and 2.4-fold, respectively, compared with controls. Furthermore, E5555 did not prolong bleeding time in guinea pigs at the highest tested dosage of 1000mg/kg. The drug interactions between E5555 and tissue plasminogen activator (tPA) were evaluated. Intravenous administration of 1mg/kg tPA significantly prolonged bleeding time, and its effects were not altered by the oral co-administration of 300mg/kg E5555. These results suggest that E5555 could be a therapeutic option for atherothrombotic disease.
AuthorsMotoji Kogushi, Toshiyuki Matsuoka, Tsutomu Kawata, Hiroko Kuramochi, Shinki Kawaguchi, Kimiyo Murakami, Hironobu Hiyoshi, Shuichi Suzuki, Tetsuya Kawahara, Akiharu Kajiwara, Ieharu Hishinuma
JournalEuropean journal of pharmacology (Eur J Pharmacol) Vol. 657 Issue 1-3 Pg. 131-7 (Apr 25 2011) ISSN: 1879-0712 [Electronic] Netherlands
PMID21300059 (Publication Type: Journal Article)
CopyrightCopyright © 2011 Elsevier B.V. All rights reserved.
Chemical References
  • Blood Coagulation Factors
  • E 5555
  • Fibrinolytic Agents
  • Imines
  • Pyridines
  • Receptors, Thrombin
  • Thrombin
Topics
  • Administration, Oral
  • Animals
  • Arteries (drug effects, physiopathology)
  • Blood Coagulation Factors (metabolism)
  • Fibrinolytic Agents (administration & dosage, pharmacology)
  • Guinea Pigs
  • Hemorrhage (physiopathology)
  • Humans
  • Imines (administration & dosage, pharmacology)
  • Male
  • Platelet Aggregation (drug effects)
  • Pyridines (administration & dosage, pharmacology)
  • Receptors, Thrombin (antagonists & inhibitors, metabolism)
  • Thrombin (pharmacology)
  • Thrombosis (metabolism, physiopathology, prevention & control)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: